Key result
Chronic ACE inhibition with cilazapril reduced cardiac hypertrophy and improved coronary vascular reserve by more than 50% in spontaneously hypertensive rats with developed hypertension.
Why the study?
Does chronic ACE inhibition with cilazapril improve coronary vascular reserve and reduce cardiac hypertrophy in spontaneously hypertensive rats with developed hypertension?
Population
Spontaneously hypertensive rats (SHR) with developed hypertension (3-8 months of age)
Comparison
Cilazapril treatment from 3 to 8 months of age vs Placebo
Design
Preclinical
Follow-up
5 months (from 3 to 8 months of age)
Authors
Loading...
Hypothesis-generating in hypertensive rat models; leaves open translation to human coronary reserve or hypertrophy management.
Does chronic ACE inhibition with cilazapril improve coronary vascular reserve and reduce cardiac hypertrophy in spontaneously hypertensive rats with developed hypertension?
Chronic ACE inhibition with cilazapril reverses cardiac hypertrophy and improves coronary microvascular morphology and reserve in rats with established hypertension.
Clozel et al. (1989) studied Hypertension and left ventricular hypertrophy. Cilazapril vs. Placebo was evaluated on Cardiac hypertrophy, coronary vascular reserve, and morphology of the coronary microvasculature. Chronic ACE inhibition with cilazapril reduced cardiac hypertrophy and improved coronary vascular reserve by more than 50% in spontaneously hypertensive rats with developed hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: